SOURCE: Protectus Medical Devices, Inc.

September 13, 2010 07:30 ET

Protectus Medical CEO to Attend Rodman & Renshaw Annual Global Healthcare Conference

MINNEAPOLIS, MN--(Marketwire - September 13, 2010) -  Protectus Medical Devices, Inc. (OTCQB: PTMD), developer and marketer of innovative safety medical devices, today announced that CEO John S. Salstrom, PhD, will attend the Rodman & Renshaw Global Investment Conference to be held on September 12-15, 2010, at the New York Palace Hotel, in New York, NY.

The Rodman & Renshaw Annual Global Investment Conference was designed to be a platform for innovative growth companies like Protectus that capture macro-trends in life sciences, natural resources, emerging markets or cutting edge financing solutions.

Dr. Salstrom and his support staff will be available for one-on-one meetings and product demonstrations with investors and analysts during the conference. The company is seeking financing up to $15MM to initiate manufacturing of the Protectus Safety Syringe following very successful pre-launch demonstrations and medical industry product introductions by its 150 person sales and distribution partner, Synergistic Medical Network.

About Protectus Medical Devices, Inc.
Protectus Medical Devices, Inc. (PTMD, formerly, E-18 Corp.), operating through its wholly owned subsidiary, SquareOne Medical, Inc., develops and markets innovative safety medical percutaneous devices that, collectively, have the potential to dramatically reduce needlestick injuries for medical professionals worldwide. In the nearly $5 billion global hypodermic syringe market, the Protectus Safety Syringe, the Company's lead product, is the only fully automatic, self-sheathing hypodermic safety syringe that currently meets the functional definition of "Self-Sheathing" mandated by the U.S. Federal Government. None of the manufacturers of other devices on the market can make this claim. Protectus Medical Devices has successfully patented its automatic, self-sheathing hypodermic safety syringe product, and, based on the results of full comparison clinical trials, the Protectus Safety Syringe (formerly the SquareOne Safety Syringe) has received the required 510(k) permission from the U.S. FDA to manufacture and market the device in the U.S. More information about the Company may be found at

Forward-Looking Statements
This release contains "forward-looking statements" for purposes of the Securities and Exchange Commission's "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. These forward-looking statements are subject to various risks and uncertainties that could cause the business and financial results of Protectus Medical Devices, Inc. to differ materially from those currently anticipated, including the risk factors identified in the filings of Protectus Medical Devices, Inc. with the Securities and Exchange Commission.

Contact Information

  • Company Contact:
    John S. Salstrom, Ph.D.
    President and CEO
    Protectus Medical Devices, Inc.

    Investor Relations Contact:
    Adam Holdsworth
    Investor Relations Group
    New York, NY